Latest Media Releases (Page 3) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - Successful completion of Share Purchase Plan (ASX:IIQ)

Highlights: -- IIQ successfully completed its share purchase plan with applications totalling A$7.293 million, exceeding its initial target of A$2 million. -- Directors exercised discretion...read more

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results (ASX:IMM)

SYDNEY, AUSTRALIA – July 3rd, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Immutep - Webcast slides for new Efti clinical data in 1st line HNSCC (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Positive topline results from ph2b in head & neck cancer (ASX:IMM)

Efti in combination with KEYTRUDA® (pembrolizumab) in first line head and neck squamous cell carcinoma (1L HNSCC) led to overall response rates that exceed KEYTRUDA monotherapy a...read more

Immutep signs agreement for anti-LAG-3 small molecules (ASX:IMM)

SYDNEY, AUSTRALIA – 25 June 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more

Immutep completes underwritten retail entitlement offer (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) is pleased to announce the completion of the retail component of its fully underwritten Entitlement Offer (details of which were a...read more

INOVIQ lodges SPP and Options Prospectus (ASX:IIQ)

INOVIQ Limited (ASX: IIQ) (INOVIQ or the Company) is pleased to announce that it has successfully completed the issue of 13,500,000 placement shares to institutional and sophisticated investors toda...read more

INOVIQ - Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ isolates brain-derived exosomes in Alzheimer's (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. NEURO-NET captures exosomes secrete...read more

INOVIQ completes $7m placement (ASX:IIQ)

Highlights: -- INOVIQ successfully completed a A$7 million placement to institutional and sophisticated investors1 at A$0.50 per share. -- INOVIQ Board and Management have participated in the...read more

Immutep letter to ineligible shareholders (ASX:IMM)

On Monday, 3 June 2024, Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or Company) announced a fully underwritten placement to institutional investors of new fully paid ordinary shares in Immut...read more

Immutep retail entitlement offer booklet (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep) is pleased to announce that it has today despatched a copy of the retail offer booklet (and accompanying personalised entitlement and acceptance ...read more

Immutep completes institutional pro-rata offer & placement (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Insti...read more

Immutep announces Ph 3 clinical trial collaboration with MSD (ASX:IMM)

-- Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) -- TACTI-004...read more

Immutep Capital Raising Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Viewing: 31 - 45 of 200 Previous | Next